People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

Authors :: Bartalucci, C
Baldi, F
Ricci, E
Orofino, G
Menzaghi, B
Ferrara, S
Pellicano', G
Squillace, N
Sarchi, E
Pontali, E
Cenderello, G
Bargiacchi, O
Piccica, M
Carleo, M
Cascio, A
De Socio, G
Bonfanti, P
Di Biagio, A
Bartalucci C.
Baldi F.
Ricci E.
Orofino G.
Menzaghi B.
Ferrara S.
Pellicano' G. F.
Squillace N.
Sarchi E.
Pontali E.
Cenderello G.
Bargiacchi O.
Piccica M.
Carleo M. A.
Cascio A.
De Socio G. V.
Bonfanti P.
Di Biagio A.
Bartalucci, C
Baldi, F
Ricci, E
Orofino, G
Menzaghi, B
Ferrara, S
Pellicano', G
Squillace, N
Sarchi, E
Pontali, E
Cenderello, G
Bargiacchi, O
Piccica, M
Carleo, M
Cascio, A
De Socio, G
Bonfanti, P
Di Biagio, A
Bartalucci C.
Baldi F.
Ricci E.
Orofino G.
Menzaghi B.
Ferrara S.
Pellicano' G. F.
Squillace N.
Sarchi E.
Pontali E.
Cenderello G.
Bargiacchi O.
Piccica M.
Carleo M. A.
Cascio A.
De Socio G. V.
Bonfanti P.
Di Biagio A.
Publication Year :: 2024
Abstract: Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.

Tools